Wave Life Sciences Ltd. (WVE) on Monday reported positive interim results from its first-in-human INLIGHT trial evaluating WVE-007 for obesity, sending the company's shares up more than 70% in pre-market trading.Following a single 240 mg dose, WVE-007 improved body composition at three months versus baseline, with a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass, while no significant changes were observed in the placebo group. The treatment was generall ...

Positive Interim Clinical Data from INLIGHT Trial of WVE-007 in Obesity Investor Presentation December 8, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ther ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved mus ...

Core Insights - Wave Life Sciences Ltd. is set to announce interim data from the Phase 1 INLIGHT clinical trial for WVE-007, an investigational treatment for obesity, on December 8, 2025 [1] - The company utilizes its proprietary SpiNA design in the development of WVE-007, which targets INHBE mRNA linked to obesity [3] Group 1: WVE-007 Overview - WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, which has shown potential in improving body composition and reducing the risk of type 2 diabetes and cardiovascular disease [3] - Preclinical studies indicate that WVE-007 can lead to adipocyte shrinkage, reduced inflammation, and improved insulin sensitivity [3] - When used in conjunction with semaglutide, WVE-007 demonstrated a doubling of weight loss in mice and prevented weight regain after stopping semaglutide [3] Group 2: INLIGHT Clinical Trial - The INLIGHT trial is a first-in-human study evaluating WVE-007 in adults with overweight or obesity, focusing on safety, tolerability, and various health metrics [4] - The trial employs a 3:1 active to placebo ratio and is being conducted at multiple sites, including locations in the US [4] Group 3: Company Background - Wave Life Sciences is a biotechnology firm dedicated to RNA medicines, with a diverse pipeline addressing conditions such as obesity, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy [5] - The company's PRISM® platform integrates various RNA-targeting modalities, enabling innovative treatments for both rare and common diseases [5] - Wave Life Sciences is headquartered in Cambridge, MA, and aims to transform human health through scientific breakthroughs [5]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Its been five months since I upgraded my rating on Wave Life Sciences Ltd. ( WVE ) from a Hold to a Buy, with shares trading at $7. There has been some volatility since - mainly toEdmund Ingham is a biotech consult ...

Summary of Wave Life Sciences Conference Call Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Focus**: Building a fully integrated RNA medicines company capable of unlocking the potential of genetic medicines, particularly in RNA editing and siRNA technologies [3][4][39] Key Programs and Developments 1. Inhibin E (WVE-007) - **Target**: Obesity, focusing on fat loss without impacting lean mass - **Mechanism**: Utilizes siRNA to knock down inhibin E, leading to significant fat loss while preserving muscle mass - **Preclinical Results**: Demonstrated a 70% reduction in activin E levels in DIO mice, translating to fat loss equivalent to GLP-1s without affecting lean mass [10][12][13] - **Clinical Data**: - 75 mg cohort showed a 55% reduction in activin E sustained over six months - 240 mg cohort achieved a 75% reduction at day 29, with ongoing decline [13][14] - **Future Outlook**: Q4 will provide three-month data on the 240 mg cohort, with further insights expected in Q1 2026 [14][20] 2. Alpha-1 Antitrypsin Deficiency (AATD) - **Mechanism**: RNA editing to convert Z protein to M protein, enhancing protein levels in patients - **Clinical Results**: At the lowest dose, patients showed a return to near-normal levels of total protein, with significant increases in M protein [32][34] - **Upcoming Data**: Focus on the 400 mg dose cohort to assess durability and editing efficiency [32][37] 3. PNPLA3 Program (WVE-008) - **Target**: Liver disease associated with homozygous mutations - **Potential Impact**: Could address a large patient population (approximately 9 million) at risk of liver diseases, with a unique mechanism that siRNAs cannot treat [39][40] Industry Context and Market Opportunity - **Obesity Treatment Landscape**: The company aims to shift the paradigm in obesity treatment from frequent dosing (weekly/monthly) to potentially once or twice a year with their siRNA therapies, addressing a significant global health issue [27][28] - **Market Size**: The global obesity market presents a substantial opportunity, with the potential to treat a billion patients worldwide [27] Important Considerations - **Kinetics of Fat Loss**: The company emphasizes the importance of understanding the kinetics of fat loss versus total weight loss, particularly in the context of preserving muscle mass [18][19][21] - **Regulatory Perspective**: The FDA's framing of healthy weight loss has influenced the company's approach to defining success in their clinical trials [17][18] Conclusion - Wave Life Sciences is positioned to make significant advancements in genetic medicine, particularly in obesity and liver disease, with promising data expected in the near future. The focus on innovative RNA technologies and the potential for long-term treatment regimens could disrupt current treatment paradigms in these areas [39][40]

Core Insights - Wave Life Sciences Ltd. (NASDAQ:WVE) is recognized as one of the best small-cap biotech stocks to buy due to its significant upside potential [1] - Jefferies maintains a "Buy" rating on Wave Life Sciences, with a price target of $26, citing improved competitive positioning following the failure of Korro Bio's KRRO-110 in a clinical trial [2] - The company reported Q3 2025 revenue of $7.6 million, which fell short of analyst expectations of $12.89 million, but reduced its net loss from $61.8 million in Q3 2024 to $53.9 million [3] Financial Performance - Wave Life Sciences reported Q3 2025 revenue of $7.6 million, missing analyst forecasts of $12.89 million [3] - The net loss decreased from $61.8 million in Q3 2024 to $53.9 million in Q3 2025, despite an increase in R&D and G&A expenses to $45.9 million and $18.1 million respectively [3] - The increased costs are attributed to ongoing investments in clinical programs, particularly the WVE-007 trial [3] Operational Outlook - The company has extended its cash runway through Q2 2027, ensuring operational continuity and funding for ongoing clinical and development initiatives [4] - Wave Life Sciences is well-positioned to advance its clinical-stage pipeline, focusing on RNA-based therapies and strategic expansion of its product development programs [4] Company Overview - Wave Life Sciences is a clinical-stage biotech company that develops and commercializes RNA medicines using its proprietary PRISM discovery and drug development platform [5]

Core Insights - Several small-cap healthcare and biotech companies experienced significant price increases in after-hours trading following earnings updates or upcoming financial disclosures [1] Company Summaries - MacroGenics, Inc. (MGNX) saw a 10.2% rise to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported a third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, year-over-year. Revenue fell to $72.8 million from $110.7 million [2] - SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of approximately $44.3 million [3] - Standard BioTools Inc. (LAB) increased by 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session [4] - KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63% [5] - Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday, with analysts anticipating a loss of $0.10 per share and revenue of $3.52 million [6] - Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. The company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year [7]

Core Viewpoint - Wave Life Sciences Ltd reported disappointing third-quarter financial results, missing both earnings and sales expectations, but highlighted significant clinical progress in its pipeline, particularly with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency [1][2]. Financial Performance - The company reported quarterly losses of $0.32 per share, which was worse than the analyst consensus estimate of losses of $0.30 per share [1]. - Quarterly sales amounted to $7.608 million, falling short of the analyst consensus estimate of $11.130 million [1]. Clinical Developments - Wave Life Sciences achieved key clinical objectives with WVE-007 and WVE-006, reinforcing its leadership in RNAi and RNA editing [2]. - WVE-007 is positioned to potentially disrupt the obesity treatment landscape, offering advantages such as fat loss induction, muscle preservation, and improved cardiometabolic health with less frequent dosing compared to existing treatments [2]. Analyst Ratings and Price Targets - Following the earnings announcement, analysts adjusted their price targets for Wave Life Sciences: - Wells Fargo maintained an Overweight rating but lowered the price target from $18 to $16 [5]. - Wedbush maintained an Outperform rating and raised the price target from $18 to $20 [5]. Market Reaction - Following the announcement, Wave Life Sciences shares increased by 3.1%, trading at $7.26 [2].

Core Insights - Wave Life Sciences Ltd reported worse-than-expected third-quarter financial results, with losses of 32 cents per share, missing the analyst consensus estimate of 30 cents per share, and quarterly sales of $7.608 million, falling short of the $11.130 million estimate [1] Financial Performance - The company reported quarterly losses of 32 cents per share, which was higher than the expected loss of 30 cents per share [1] - Quarterly sales amounted to $7.608 million, missing the analyst consensus estimate of $11.130 million [1] Clinical Developments - The company achieved key clinical objectives with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, indicating the effectiveness of its proprietary chemistry [2] - WVE-007 is positioned to potentially disrupt the obesity treatment landscape, with advantages such as inducing fat loss, preserving muscle, and improving cardiometabolic health, while avoiding the class effects of GLP-1s [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Wave Life Sciences shares gained 3.1%, trading at $7.26 [2] - Wells Fargo analyst Benjamin Burnett maintained an Overweight rating on the stock but lowered the price target from $18 to $16 [5] - Wedbush analyst Yun Zhong maintained an Outperform rating and raised the price target from $18 to $20 [5]